ReWalk Robotics Ltd. announced it has completed internal laboratory testing and design review to begin clinical studies and initial production of a “soft suit” exoskeleton for patients who have experienced a stroke.
The new system, called Restore, will be the first product in ReWalk’s expansion into new technologies to serve mobility-challenged patients, according to a press release. The system is designed to provide real-time adjustable walking assistance for patients. The compact suit utilizes key features from structural exoskeleton designs, without the size, structure and expense of current designs, according to the release.
The Restore system uses cable technologies powered by software and involves mechanics similar to those used in the ReWalk exoskeleton system. Cables are connected to fabric-based designs that attach to the legs and foot, according to the release.
“Achieving successful laboratory testing and design review processes with the Restore system is a milestone that advances our efforts for commercialization,” Larry Jasinski, chief executive officer of ReWalk, said in the release. “The potential of these soft suit deigns to expand the utilization of robotic technologies initially with stroke patient in rehab — and in the future for community use — is meaningful. Research into applications, such as multiple sclerosis and Parkinson’s disease, is the next horizon.”
ReWalk plans to submit applications for CE and FDA clearances for the Restore system in in mid-2018, with anticipated commercial delivery of the Restore soft suit planned for 2018.